Product Details
Product Details
Product Specification
| Antigen | CXCL9/MIG |
| Reactivity | Mouse |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8°C as supplied. |
Kit
| Sample type | Serum; Plasma; Cell culture supernatant |
| Assay type | Sandwich (quantitative) |
| Sensitivity | 40 pg/mL |
| Range | 50 pg/mL-250000 pg/mL |
| Recovery | Cell culture supernatant: 106% |
| Assay time | 70 minutes |
| Species reactivity | Mouse |
Background
Mouse CXCL9/MIG (monokine induced by interferon-gamma) is a key chemokine secreted by IFN-γstimulated activated monocytes, macrophages, and endothelial cells, and belongs to the ELRnegative CXC chemokine subfamily. As a core biomarker of Th1type immune responses, CXCL9 specifically binds to its receptor CXCR3 to efficiently recruit CD4+ Th1 cells, CD8+ cytotoxic T cells, and NK cells to sites of inflammation or tumors, while also participating in immune balance regulation by antagonizing Th2 responses. In addition, its ELRnegative nature confers a unique ability to inhibit vascular endothelial cell proliferation and angiogenesis, which gives CXCL9 a dual role in the tumor microenvironment—it can recruit cytotoxic immune cells to mediate antitumor effects (via CXCR3B), yet it may also promote tumor migration through specific signaling pathways (via CXCR3A). Based on these functions, quantitative detection of CXCL9 holds significant application value in the evaluation of cancer immunotherapies, early warning of organ transplant rejection, mechanistic studies of metabolic inflammationassociated diseases such as MAFLD/MASH, and monitoring of infectious immunity. Thus, CXCL9 serves as a critical biomarker reflecting cellular immune activity and the inflammatory status of the microenvironment.
